Skip to content

Global Startups Research & Market Intelligence REPORT

Identify Partners Series

Immuno-oncology Startups


Latest Report covering World’s Largest Number of Active Immuno-Oncology Drug Developers


Top 400

Immuno Oncology Startups

Provides Complete Landscape on Latest Immuno-Oncology Drug Development covering Emerging Technologies, Partnering and Funding Status among Startups

Immuno-Oncology Startups 2020 (First Edition)

Report Covers all Aspects of Immuno-Oncology Drug Development Intelligence


largest coverage

providing intelligence at fingertips


Worldwide Extensive Coverage


Formed after 2010; with Market Valuation less then $500Mn USD


Largest Early Stage Developmental Pipeline Details

1 +

Covers exclusive I/O focused Deals, partnering with BIG Pharma, CROs etc.

Perfect B2B Solution

Unique first in class Intelligence Report

Provides Complete Landscape on Latest Immuno-Oncology Drug Development covering Emerging Technologies, Partnering and Funding Status in the Domain.
Also, Startups having proper funding, technologies and pipeline are only included.
No Acquired, Merged or Dormant Stage I/O Drug Developer is included.

Need of the Report

  • From last few years maximum number of Startups are opting for Immuno-Oncology drug discovery challenge.
  • Higher Collaboration to aid drug development process: Immuno-Oncology drug discovery is evolving and requires timely strong support and inputs across the channel.
  • Well-funded, thus offers immense partnering opportunities, but lacks proper system to track emerging opportunities.
  • Currently available resources cover only limited number of known companies that too developing late stage clinical molecules. But real challenge lies in timely identifying the startup, having potential of future shining star.
  • Virtually no system to track, Startups outside U.S and China, which contributes to 30% of total established startups in I/O domain.

Report is highly precise and designed keeping in mind to keep information intact, informative and self explanatory. Also, every piece of intelligence is cross validated.

Only facts, no guess work.

330+ Pages present complete picture of individual company’s pipeline, deals, partnering, funding etc. and outline individual startup’s core strength and stand with respect to other startups.

Report documents all I/O focused news/deals of every startups since incorporation. Making it perfect tool for Decision Making and a big time saver too.

Compares Oranges with Oranges.

Only Active I/O Drug Developing Startups, with no room to Diagnostic and Device companies; making data clear and impactful.

Most of the intelligence provider covers limited number of known companies, that too many of which have no links to the core title of the report. Also many renowned database too contains acquired/closed companies, thus driving final intelligence too tedious and time consuming exercise.

All our reports provides comprehensive intelligence, with largest active industry coverage and avoids investing money on other similar resources. Thus, saves lots of resources in terms of time and money, in identifying new partnering opportunities.

Each year, we publish very small number of comprehensive reports and are experts in identifying and tracking startups. We maintain our own database and track’s every individual company.

From last 10 years, our team exclusively providing marketing intelligence in field of Oncology and Neurology Drug Development.

334 pages - full of insights

intelligence supercharged

Our Report Buyers

Trusted by Over 150+ Companies

(Since 2012 Onward)

Identify and Partner

Prior to others